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483A New Peptide Input to
Learning and Addiction
In this issue of Neuron, Borgland et al. report that the
arousal-associated peptide orexin enhances LTP-like
changes in glutamatergic excitability of ventral teg-
mental dopamine neurons. This parallels a similar
effect of corticotropin-releasing factor and suggests
a form of neuroadaptation that increases the likeli-
hood of addiction relapse.
Borgland and colleagues (Borgland et al., 2006) report
that orexin A input to the ventral tegmental area (VTA)
(1) potentiates, by a PKC/PLC pathway, NMDA recep-
tor-mediated excitatory postsynaptic currents in dopa-
mine neurons; (2) modulates NMDA receptor composi-
tion; (3) translocates NMDA receptors to the synapse;
(4) causes AMPA receptor-mediated synaptic plasticity;
(5) facilitates cocaine-induced potentiation of excitatory
input to VTA dopamine neurons; and (6) plays a critical
role in cocaine-induced psychomotor sensitization.
These findings parallel similar findings with CRF, made
earlier by the Bonci group (Ungless et al., 2003). The
two findings link potential mechanisms of learning and
memory to mechanisms of addiction, adding an impor-
tant dimension to addiction research.
It is widely suspected that drug-induced neuroadap-
tations (and not just those of the simple memory trace
for the drug experience) differentiate the addicted from
the nonaddicted brain. While eating and sexual habits
can become compulsive to the point of risk for diabetes,
cardiovascular disease, or loss of public office, addic-
tion is seen to involve even more compulsive habits
and to require even stronger explanations and more
complex mechanisms. From this perspective, it is not
enough that addictive drugs activate brain reward cir-
cuitry more strongly or more immediately; rather, addic-
tive drugs are seen to alter the brain in ways that make
the drug more habit-forming than ‘‘natural’’ rewards
and more habit-forming for the addict than for the non-
addict. Addictive drugs do, of course, alter the brain,
and many of the alterations are long-lasting.
The findings of the Bonci group advance the field of
addiction research in three ways. First, rather than
a mechanism primarily involved in pharmacological re-
sponses to ingested cocaine, they have identified a neu-
roadaptation (sensitization of mesolimbic dopaminergicneurons to glutamatergic input) that links drug reward
circuitry to the arousal messenger orexin and, in earlier
studies (Ungless et al., 2003), to the stress messenger
corticotropin-releasing factor (CRF). Stress and arousal
are phenomena that can trigger drug-seeking in absti-
nent subjects (Shalev et al., 2002); they can get drug-
seeking started and not just maintain it once it is under
way. Here we have clues, perhaps, as to how early expe-
rience can predispose some individuals to addiction by
sensitizing the brain to emotional events.
Second, these studies begin to bring peptide neuro-
transmitters into the discussion of neuroplasticity in ad-
diction. While opioid peptide neurotransmitters have
long been studied because they act at the same recep-
tors as addictive opiates, studies of neuroadaptations
to drugs of abuse have focused largely on the ‘‘primary’’
neurotransmitters dopamine, glutamate, and GABA.
Third, these studies take an important step toward re-
lating the neuroadaptations of addiction to mechanisms
associated with the cellular basis of learning and mem-
ory (see Kelley, 2004). Orexin in the new study and CRF
in the earlier work each modulate glutamatergic activa-
tion of midbrain dopamine neurons in much the same
way as is seen in long-term potentiation. The very similar
characteristics of orexin-induced and CRF-induced
sensitization of the activation of dopaminergic neurons
by glutamate suggest a common or at least strongly
overlapping mechanism. Changes in synaptic efficacy
such as those induced by orexin and CRF are not only
likely to underlie learned stress and arousal responses
to the environment, they are also likely, perhaps in other
parts of the brain, to help consolidate the specific mem-
ories (the ‘‘remembered high’’) associated with the drug
experience.
Intraventricular (Boutrel et al., 2005) or VTA (Harris
et al., 2005) infusions of orexin are known to reinstate
drug-seeking in rodents, as do intraventricular (Shaham
et al., 1997) or VTA (Wang et al., 2005) infusions of CRF.
Ventral tegmental injections of an orexin antagonist
block the development of heroin-conditioned place
preferences (Narita et al., 2006). Inasmuch as arousal
or stress can trigger drug-seeking in drug-free animals,
the neuroadaptations discovered by the Bonci group are
important not only for how rewarding the drug is after an
animal starts taking it, but, perhaps more importantly,
for how likely the animal is to initiate drug-seeking dur-
ing periods of abstinence. Because it is during periods
of abstinence, not periods of intoxication, that addicts
seek treatment, the peptide signaling pathways for
orexin and CRF may prove to be fruitful targets in the
search for addiction medications.
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been assigned a primary role in regulating motor behav-
ior. However, the striatum can influence the cerebral
cortex via projections to the pallidum, thence to the thal-
amus, and onward to the cortex.
Dopamine might modulate schizophrenic behavior
without being fundamental to the disease’s pathophys-
iology. A direct link comes from studies reporting in-
creased numbers of dopamine D2 receptors in the stria-
tum of schizophrenic brain (Seeman and Kapur, 2000).
However, prolonged treatment with neuroleptics leads
to augmented numbers of D2 receptors, and there are
few drug-naive schizophrenics.
If hyperactivity of dopamine systems mediated by
augmented numbers of D2 receptors underlies schizo-
phrenic dysfunction, then a transgenic mouse overex-
pressing D2 receptors might provide an animal model
of schizophrenia. In this issue of Neuron, Kellendonk
et al. (2006) have aimed to create such a model by creat-
ing D2 receptor transgenic mice. Most elegant about
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and Mouse Madness
The dopamine hypothesis of schizophrenia is based
on evidence that the major antipsychotic drugs act
by blocking dopamine D2 receptors and that dopa-
mine-releasing drugs worsen symptoms. In this issue
of Neuron, Kellendonk et al. report an elegant condi-
tional transgenic mouse overexpressing dopamine
D2 receptors selectively in the striatum. Strikingly,
these animals display selective cognitive impairment
typically associated with frontal cortical defects and
abnormal dopamine markers in the prefrontal cortex,
suggesting that striatal dopamine receptors can influ-
ence cortical dopamine function.
The dopamine hypothesis of schizophrenia derives from
a concatenation of diverse evidence (Snyder, 1976). The
initial, most compelling findings were pharmacologic. In
1963, Arvid Carlsson observed changes in levels of do-
pamine metabolites in rats treated with antipsychotic
neuroleptic drugs and speculated that these may reflect
augmented firing of dopamine neurons secondary to
blockade of receptors. The ability to monitor dopamine
receptors by ligand binding permitted the discovery of
very potent and selective blockade of dopamine D2 re-
ceptors by neuroleptic drugs with molecular potencies
paralleling therapeutic potencies. Amphetamine, which
releases dopamine, selectively exacerbates schizo-
phrenic symptoms.
Patricia Goldman-Rakic (Goldman-Rakic, 1999) es-
tablished a role for the dopamine neurons that project
to the prefrontal cerebral cortex in regulating cognitive
functions that are selectively impaired in schizo-
phrenics. Dopamine projections to the prefrontal cortex
arise from the ventral tegmental area of the midbrain.
The most prominent dopamine pathway has cell bodies
in the substantia nigra with axons projecting to the cau-
date and putamen collectively called the striatum. De-
generation of this pathway gives rise to the symptoms
of Parkinson’s disease so that the striatum has generally
this system is that the transgene is conditional, being
under the control of a tetracycline response element
that can be turned off by oral administration of the anti-
biotic doxycycline. Additionally, the transgene is selec-
tively expressed in the striatum and not in other areas
of the brain that possess D2 receptors. The striatum of
the transgenic mice displays increased numbers of D2
receptor binding sites and increased effects on adenylyl
cyclase indicating that the transgenic receptors are
functional. Overall behavior of the mutant mice is normal
with unaltered locomotor activity, sensorimotor gating,
and generalized anxiety. However, the mice display sub-
stantial defects in working memory tasks and behavioral
flexibility typically associated with prefrontal cortical
function. The authors provide direct evidence that the
striatal D2 receptors somehow influence the cortex
because the mutant mice display altered glucose me-
tabolism, dopamine levels, and dopamine D1 receptor
activation in the prefrontal cortex. Reversal of the trans-
gene with doxycycline treatment does not reverse the
cognitive defects, indicating that the behavioral deficit
presumably reflects D2 receptor overexpression during
fetal life.
The Kellendonk study clearly establishes an influence
of striatal D2 receptors upon biochemical markers and
cognitive behaviors associated with the prefrontal cor-
tex. Do these findings teach us about the pathophysiol-
ogy of schizophrenia? Do these mice provide an animal
model of schizophrenia? Recent genetic studies afford
a basis for optimism. Numerous workers have had some
success in identifying specific genes linked to schizo-
phrenia. Best characterized is DISC1, a cytoskeletal pro-
tein that binds to a subtype of phosphodiesterase and
inhibits its catalytic activity (Millar et al., 2005). Because
this phosphodiesterase metabolizes cyclic AMP, which
is a second messenger for dopamine, one might specu-
late about some relationship. Weinberger and col-
leagues (Winterer and Weinberger, 2004) provided
evidence that polymorphisms in catechol-O-methyl-
transferase (COMT) impact dopamine transmission in
prefrontal cortex, prefrontal-linked cognitive behavior,
and schizophrenic behavior. Thus, it is not at all far-
fetched to envisage dopamine disturbances eliciting
schizophrenic mental aberrations. In this case, the trans-
genic mice developed by Kellendonk and colleagues
